The London Life Sciences team advised Enterprise Therapeutics Ltd (”Enterprise”), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, on the demerger and subsequent acquisition of its TMEM16A potentiator portfolio by Roche for an upfront consideration of £75 million and significant potential milestone payments. The TMEM16A portfolio is focused toward treating people with cystic fibrosis and has the potential to benefit people with other severe respiratory diseases. Enterprise is backed by leading life science investors Epidarex Capital, Forbion, IP Group, Novartis Venture Fund and Versant Ventures.

The deal follows on closely from Goodwin’s lead role on two of this year’s largest European biotech M&A transactions – advising Inflazome on its acquisition by Roche and representing KaNDy Therapeutics in its sale to Bayer. Other notable M&A transactions the group has advised on since June this year include advising: 

  • European digital health company Zesty Limited on its sale to Induction Healthcare Group Plc, the number one healthcare collaboration app in the UK;
  • Dotmatics, a scientific informatics company, on its acquisition of all of the outstanding equity interests of US-based scientific lab data automation company BioBright; and
  • Symprove, a UK-based probiotics manufacturer, on its sale of a majority stake to private equity firm bd-capital.

The Goodwin team on the Enterprise matter was led by Graham Defries and Andrew Harrow and included Malcolm Bates, Gretchen Scott, Michael Grainger, Kenny Walker-DurrantMatthew Shelley, Daniel Karelitz, Nicole Spiteri, Grace Wirth and James Devendorf.

For additional details, please read the Enterprise press release.